医学临床研究
  2025年4月9日 星期三           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2020, Vol. 37 Issue (10): 1511-1513    DOI: 10.3969/j.issn.1671-7171.2020.10.021
  论著 本期目录 | 过刊浏览 | 高级检索 |
SOX18在前列腺癌中的表达及与患者远期预后的关系
许雪伟, 原双, 苏万, 鋆孙怡
山东省立第三医院,山东 济南 250031
SOX18 Expression with Patients' Long-term Prognosis in Prostate Cancer
XU Xue-wei, YUAN Shuang, SU Wan-yun, et al
Shandong Provincial Third Hospital, Jinan Shandong, 250031,China
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】 探讨性别决定区Y框蛋白18(SOX18)在前列腺癌中的表达及与患者远期预后的关系。【方法】 选择2013年1月至2018年3月本院收治的140例前列腺癌患者(观察组)的临床资料,同时选取良性前列腺增生组织112例作为对照组,采用免疫组化染色法检测SOX18表达,随访患者预后情况。【结果】 观察组SOX18阳性表达率为70.00%(98/140),显著高于对照组的40.18%(45/112),差异有统计学意义(χ2=22.545,P<0.05)。SOX18阳性患者中位总生存时间为50个月(95%CI:43.81~56.19),明显短于SOX18阴性患者的70个月[95%CI(66.92~73.08)],差异有统计学意义(χ2=19.649,P<0.05)。将SOX18阳性表达、年龄、高血压、糖尿病、TNM分期等临床病理指标作为自变量,预后生存情况等作为因变量进行COX回归分析,结果显示TNM分期、Gleason评分、SOX18表达是前列腺癌患者预后的影响因素(HR=2.748、2.392、1.426,P<0.05)。【结论】 前列腺癌患者SOX18阳性表达率高,与临床分期、病理分级、PSA及Gleason有一定关系,同时对患者预后有一定影响。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
许雪伟
原双
苏万
鋆孙怡
关键词 前列腺肿瘤/病理学SOXF转录因子类预后    
Abstract【Objective】 To investigate the expression of sex-determining region Y-box protein 18 (SOX18) in prostate cancer and its relationship with long-term prognosis. 【Methods】 A total of 140 patients with prostate cancer treated in our hospital from January 2012 to March 2017 were selected as the prostate cancer group, and 112 patients with benign prostatic hyperplasia were selected as the control group. The expression of SOX18 was detected by immunohistochemical staining, and the prognosis of patients was followed up. 【Results】 The positive expression rate of SOX18 in prostate cancer group was 70.00% (98/140), which was significantly higher than that in control group 40.18% (45/112). The difference was statistically significant (P<0.05). The positive expression rates of SOX18 in patients with TNM stage Ⅲ-Ⅳ, pathological grade G3-G4, PSA level > 20 ng/mL and Gleason score≥ 8 were 88.24%, 83.05%, 88.89% and 80.49%, respectively, which were significantly higher than those in patients with stage Ⅰ-Ⅱ, G1-G2, prostate specific antigen (PSA)≤20 ng/mL and Gleason score ≤7 (P<0.05). The median overall survival time of SOX18 positive patients was 50 months, which was significantly shorter than that of SOX18 negative patients (70 months); the difference was statistically significant (P<0.05). COX regression analysis showed that TNM stage, Gleason score and SOX18 expression were the prognostic factors of prostate cancer patients (HR=2.748,2.392 and 1.426, P<0.05). 【Conclusion】 The expression of SOX18 in prostate cancer is significantly up-regulated, which are related to clinical stage, pathological grade, PSA and Gleason, and also affect the prognosis of patients.
Key wordsProstatic Neoplasms/PA    SOXF Transcription Factors    Prognosis
收稿日期: 2020-05-13     
PACS:  R737.25  
引用本文:   
许雪伟, 原双, 苏万, 鋆孙怡. SOX18在前列腺癌中的表达及与患者远期预后的关系[J]. 医学临床研究, 2020, 37(10): 1511-1513.
XU Xue-wei, YUAN Shuang, SU Wan-yun, et al. SOX18 Expression with Patients' Long-term Prognosis in Prostate Cancer. JOURNAL OF CLINICAL RESEARCH, 2020, 37(10): 1511-1513.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2020.10.021     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2020/V37/I10/1511
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn